High-Risk Acute Myeloid Leukemia

In this video, Aaron T. Gerds, MD, from the Cleveland Clinic Taussig Cancer Institute, discusses a new IDH inhibitor, olutasidenib, which was found to be well tolerated in patients with relapsed or refractory acute myeloid leukemia.

Each year in the U.S., more than 20,000 patients are diagnosed with acute myeloid leukemia — an aggressive and often lethal malignancy — and more than half this number of patients die.